Welcome to our dedicated page for Zealand Pharma A/S news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on Zealand Pharma A/S stock.
News about Zealand Pharma A/S (Nasdaq: ZEAL) centers on its work as a biotechnology company focused on peptide-based medicines for obesity and metabolic health, as well as its collaborations, clinical data and capital markets activity. Company announcements and partner press releases highlight progress across clinical trials, strategic agreements and shareholder developments.
Readers following ZEAL news will find updates on clinical programs such as BI 456906, a dual glucagon/GLP‑1 receptor agonist co‑invented with Boehringer Ingelheim. Phase II trial results reported by Boehringer Ingelheim and Zealand Pharma showed dose‑dependent weight loss in people living with obesity or overweight and in people with type 2 diabetes, reflecting the company’s focus on metabolic pathways. News also covers scientific presentations at major meetings, where Zealand Pharma shares preclinical and clinical data on investigational peptide candidates including dapiglutide, ZP8396 and ZP6590 for potential obesity and metabolic indications.
Another recurring news theme is strategic collaboration. For example, Zealand Pharma and OTR Therapeutics announced a multi‑program strategic collaboration and license agreement to discover and develop novel therapeutics for multiple targets in metabolic diseases. Under this agreement, OTR Therapeutics leads research and preclinical development using its proprietary discovery platform, while Zealand Pharma is responsible for clinical development, regulatory submissions and global commercialization.
Investors can also track company announcements on directed share offerings, private placements, capital increases and major shareholder notifications, which explain how Zealand Pharma raises funds to support its pipeline and disclose changes in ownership stakes. For ongoing insight into ZEAL’s clinical progress, partnerships and corporate actions, this news feed aggregates relevant releases and partner communications in one place.
Zealand Pharma A/S (Nasdaq: ZEAL) will participate in two upcoming investor conferences in June 2022: the Jefferies 2022 Global Healthcare Conference on June 10 and the Goldman Sachs Global Healthcare Conference on June 13. The Jefferies presentation will start at 8:00 a.m. EST and will be available via a live webcast, which will be archived afterward on the company's website. Zealand Pharma focuses on developing peptide-based medicines, having advanced over 10 drug candidates into clinical development.
Zealand Pharma has appointed David M. Kendall, M.D., as its new Chief Medical Officer, following the recent appointment of Adam Steensberg as CEO. Dr. Kendall, who has over 35 years of experience in diabetes and metabolic disease, previously served as Senior Global Medical Advisor at Zealand. His leadership is expected to enhance the company's clinical programs as they refocus on advancing their peptide-based medicine pipeline. Zealand has a portfolio of over 10 drug candidates, with two already on the market and three in late-stage development.
Zealand Pharma announced a directed issue and private placement of 2,892,368 new shares, amounting to approximately 6.6% of its existing share capital. The gross proceeds are expected to total DKK 274.8 million (approximately $40.4 million), which will enhance the company's ability to execute its refocused strategy emphasizing R&D and commercial partnerships for late-stage products. The new shares will be priced at DKK 95 each, reflecting the current market price. This funding extends Zealand's cash runway into H2 2023.
Zealand Pharma A/S (Nasdaq: ZEAL) announced transactions involving its shares by individuals in managerial positions, reflecting ongoing movements within the company. The biotechnology firm, based in Copenhagen, specializes in peptide-based medicines, with over 10 drug candidates currently in clinical development. Among its marketed products are V-Go® and Zegalogue®. Zealand Pharma's collaborations with Boehringer Ingelheim and AstraZeneca may enhance its market reach.
Further details can be found in the attachments included in the release.
Zealand Pharma announced five accepted presentations at the 82nd Annual American Diabetes Association Scientific Sessions, showcasing initial clinical data on its GLP-1/GLP-2 dual agonist, dapiglutide. The presentations will include Phase 1 data demonstrating significant weight loss and preclinical insights into the antidiabetic potential of ZP8396, a long-acting amylin analogue. These findings reinforce the company’s commitment to developing innovative treatments for diabetes and obesity, with presentations scheduled in New Orleans from June 3-7, 2022.
Zealand Pharma has announced a long-term incentive program (LTIP) for its Corporate Management and employees, granting a total of 266,223 performance stock units (PSUs), 99,420 restricted stock units (RSUs), and 863,156 warrants. The total cost of this program amounts to DKK 69.4 million. The PSUs are tied to operational and market-based performance targets, while the RSUs will vest over three years. The LTIP aims to align management interests with shareholder goals, enhancing talent retention and motivation.
Zealand Pharma A/S (Nasdaq: ZEAL) has reported transactions in its securities by individuals with managerial responsibilities. This announcement follows a standard protocol for transparency in trading activities. Zealand Pharma focuses on peptide-based medicines, with two drugs currently on the market and three in late-stage development. The company collaborates with major pharmaceutical partners, enhancing its market reach. The release emphasizes the importance of proper communication regarding trades by executives and insiders, reinforcing Zealand's commitment to shareholder transparency.
Zealand Pharma announced positive results from a Phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism (CHI). The trial demonstrated a statistically significant reduction of 55% in intravenous glucose requirements compared to placebo. Dasiglucagon was well-tolerated in the trial, with 11 out of 12 patients continuing into a long-term safety study. Zealand Pharma plans to submit a New Drug Application to the FDA by the end of 2022, aiming to provide a new treatment for this ultra-rare condition, which hasn't seen a developed medicine in over three decades.
Zealand Pharma has entered into an asset purchase agreement with MannKind Corporation to sell the V-Go insulin delivery device for $10 million and additional sales milestones. The deal also includes certain inventory and employees. This agreement aligns with Zealand's strategy to find partners for commercial and late-stage assets while focusing on R&D for new peptide therapeutics. The acquisition is expected to close in May 2022 and does not affect Zealand's 2022 financial guidance.
Zealand Pharma has announced corrections regarding its previous release about transactions in its securities by managerial personnel. The corrected share price at market close on May 12, 2022, was reported at DKK 73.75, lower than the previously stated DKK 75.75. This change affects the overall calculated value for participants involved in the transactions. Zealand Pharma, focusing on peptide-based medicines, currently has two marketed drugs and several candidates in late-stage development.